Cidara's Narrow Spread: The Bidding War Is Over

Cidara Therapeutics, Inc. surges to $217 on a bid by Merck & Co., Inc. valuing shares at $221.50. Learn more about CDTX stock ...

Roivant Sciences: Brepocitinib And Roadmap Still Underpriced

Roivant Sciences Ltd.'s innovative model and breakthrough autoimmune drug pipeline make it a strong buy. Click here to read ...

Immunovant, Inc. (NASDAQ:IMVT) Q2 2026 Earnings Call Transcript

Q2 2026 Earnings Call Transcript November 10, 2025 Immunovant, Inc. misses on earnings expectations. Reported EPS is ...

Roivant Sciences Ltd. (NASDAQ:ROIV) Q2 2026 Earnings Call Transcript

Q2 2026 Earnings Call Transcript November 10, 2025 Roivant Sciences Ltd. beats earnings expectations. Reported EPS is ...
The Manila Times

Immunovant Provides Corporate Updates and Reports Financial Results for the Second Quarter Ended September 30, 2025

Study in uncontrolled Graves’ disease (GD) patients treated for 24 weeks showed first-ever potentially disease-modifying outcome with six-month off-treatment dataIMVT-1402 development is progressing ...

Roivant Reports Financial Results for the Second Quarter Ended September 30, 2025, and Provides Business Update

BASEL, Switzerland and LONDON and NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today reported its financial results for the second quarter ended September 30, 2025, and provided ...